Comparison of the Recombinant Versus Highly-Purified, Urinary Follicle-Stimulating Hormone (r-FSH vs. HP-uFSH) in the Polycystic Ovary Syndrom Patients who had Antagonist Cycle with In Vitro Fertilization-Embryo Transfer

Creative Commons License

Kara M., Kutlu T., Sofuoglu K.

TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, vol.31, no.4, pp.775-779, 2011 (SCI-Expanded) identifier


Objectives: Although there are a number of studies on the costs and efficacy of the drugs which are used in in vitro fertilization (IVF), the data obtained in antagonist cycles of polycystic ovary syndrome (PCOS) cases are still controversial. The aim of the study was to evaluate follicular development, pregnancy outcome and cost-effectiveness comparing r-FSH and HP-u FSH in antagonist cycles of PCOS cases. Material and Methods: A total of 102 patients were included in the study. Patients were treated using the same stimulation protocol. r-FSH (n= 54) or HP-u FSH (n= 48) were given according to the clinician's choice and the patient's preference. Results: r-FSH treatment required significantly less amount to induce follicular development and resulted in higher plasma levels of estradiol on the day of human chorionic gonadotropin (hCG) injection. Although pregnancy rate in the r FSH group was higher than HP u FSH group (40.7% vs. 33.3%), the difference was not statistically significant. Total FSH dose was significantly lower in r FSH group comparet to HP-uFSH (1396.3 +/- 131.6 iu vs.1820.14 +/- 174.6 iu). Conclusion: r-FSH is more efficient than HP-u FSH in terms of total FSH dose. The Follicular development and endometrial thickness on the day of hCG were better in the r-FSH group, however these differences were not statistically significant. Although r-FSH is more expensive, the final treatment cost with r-FSH per pregnancy was slightly lower although this difference was not statistically significant.